ArticleOncology letters2025
Integrated analysis of FANCE expression and its regulatory role in the immune microenvironment of oral squamous cell carcinoma.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral squamous cell carcinoma (OSCC) presents a significant health challenge owing to its complex origin and limited treatment success. The precise function of Fanconi anemia complementation group E (FANCE), a key gene involved in DNA repair in OSCC, remains unclear. The present study performed bioinformatics analysis of The Cancer Genome Atlas dataset and cellular experiments to demonstrate that FANCE is significantly upregulated in OSCC. Enhanced FANCE expression was associated with poor survival outcome in patients with OSCC. Knockdown of FANCE inhibited OSCC cell proliferation and migration. Moreover, a negative correlation was observed between FANCE expression and immune cell markers. Collectively, these findings suggest that FANCE is a potential oncogene in OSCC and a prognostic biomarker that may play a role in modulating the OSCC microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.